JPMorgan Chase & Co. Has $246.47 Million Stake in STERIS plc (NYSE:STE)

JPMorgan Chase & Co. lessened its stake in shares of STERIS plc (NYSE:STE - Free Report) by 0.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,016,196 shares of the medical equipment provider's stock after selling 2,776 shares during the period. JPMorgan Chase & Co. owned 1.03% of STERIS worth $246,468,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. West Coast Financial LLC lifted its position in shares of STERIS by 2.8% during the 3rd quarter. West Coast Financial LLC now owns 1,640 shares of the medical equipment provider's stock worth $398,000 after purchasing an additional 45 shares during the last quarter. SkyView Investment Advisors LLC lifted its holdings in shares of STERIS by 1.6% during the third quarter. SkyView Investment Advisors LLC now owns 3,153 shares of the medical equipment provider's stock worth $765,000 after buying an additional 51 shares during the last quarter. Waterloo Capital L.P. grew its stake in shares of STERIS by 3.2% in the second quarter. Waterloo Capital L.P. now owns 1,916 shares of the medical equipment provider's stock worth $421,000 after acquiring an additional 59 shares during the last quarter. Metis Global Partners LLC increased its position in STERIS by 1.6% during the third quarter. Metis Global Partners LLC now owns 5,450 shares of the medical equipment provider's stock worth $1,322,000 after acquiring an additional 84 shares during the period. Finally, Insigneo Advisory Services LLC raised its stake in STERIS by 6.0% during the 3rd quarter. Insigneo Advisory Services LLC now owns 1,686 shares of the medical equipment provider's stock valued at $409,000 after purchasing an additional 95 shares during the last quarter. Institutional investors own 94.69% of the company's stock.

STERIS Price Performance

Shares of STE stock traded up $0.48 during trading hours on Tuesday, hitting $205.56. The company had a trading volume of 370,247 shares, compared to its average volume of 501,682. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.55 and a current ratio of 2.41. The firm's fifty day moving average is $216.43 and its 200 day moving average is $225.79. The firm has a market capitalization of $20.29 billion, a price-to-earnings ratio of 46.93 and a beta of 0.83.

STERIS (NYSE:STE - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $2.14 earnings per share for the quarter, beating analysts' consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The firm had revenue of $1.33 billion for the quarter, compared to analysts' expectations of $1.33 billion. During the same period in the prior year, the business posted $2.03 earnings per share. The business's revenue was up 7.3% compared to the same quarter last year. On average, sell-side analysts predict that STERIS plc will post 9.1 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, December 19th. Shareholders of record on Tuesday, November 19th were given a $0.57 dividend. The ex-dividend date was Tuesday, November 19th. This represents a $2.28 dividend on an annualized basis and a yield of 1.11%. STERIS's dividend payout ratio (DPR) is presently 52.05%.

Insiders Place Their Bets

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of STERIS stock in a transaction on Monday, November 25th. The stock was sold at an average price of $217.32, for a total value of $365,532.24. Following the completion of the transaction, the senior vice president now owns 11,372 shares in the company, valued at approximately $2,471,363.04. The trade was a 12.88 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 1.14% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. StockNews.com lowered shares of STERIS from a "strong-buy" rating to a "buy" rating in a research report on Tuesday, October 29th. KeyCorp lifted their target price on STERIS from $255.00 to $265.00 and gave the stock an "overweight" rating in a research report on Tuesday, September 3rd. Piper Sandler raised STERIS from a "neutral" rating to an "overweight" rating and upped their price target for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Stephens reissued an "overweight" rating and set a $260.00 price objective on shares of STERIS in a report on Thursday, November 7th. Finally, JMP Securities restated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a research note on Monday, November 18th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, STERIS presently has an average rating of "Moderate Buy" and an average price target of $262.50.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.